Anti-Human CD257 (BAFF) (Tabalumab)
Anti-Human CD257 (BAFF) (Tabalumab)
Product No.: LT1400
Product No.LT1400 Clone Tabalumab Target BAFF Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Tabalumab, CD257, BAFF, TNFSF13b, BLYS, 1143503-67-6 Isotype Human IgG1κ Applications ELISA , FA , FC , IF , IP , N , WB |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Human ⋅ Rabbit Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Original antibody was raised against soluble human BAFF. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893903 Additional Applications Reported In Literature ? FA N IP WB ELISA IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only. Background Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects. Antigen Distribution BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells. Ligand/Receptor TACI, BCMA,APRIL ligand, BAFFR/BR3 PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cancer . Cell Biology . Costimulatory Molecules . Immuno-Oncology . Immunology . Signal Transduction . Stem Cell Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade tabalumab biosimilars are not directly addressed in the provided search results, but the principles of using biosimilars as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISAs can be inferred from general practices. Here's how biosimilars might be used in such assays: Role of Biosimilars as Calibration StandardsBiosimilars can serve as calibration standards in PK assays due to their high degree of similarity to the reference biologic drug. This similarity ensures that the biosimilar can accurately reflect the pharmacokinetic behavior of the reference drug. Use in Bridging ELISAs
Implementation in PK Bridging ELISAs
In summary, while the specific use of tabalumab biosimilars as calibration standards or reference controls in PK bridging ELISAs is not detailed in the search results, the general principles of using biosimilars in such assays involve establishing bioanalytical equivalence, creating calibration curves, and ensuring assay performance through robust validation studies. The primary models used to study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs) in the context of BAFF inhibition are not explicitly mentioned in the search results. However, based on the information provided, here's how these models could be applied: Syngeneic ModelsSyngeneic Tumor Models are widely employed in preclinical immunotherapy studies due to their immune-competent status and fully functional immune systems. These models are excellent for evaluating the efficacy of immunotherapeutic agents by analyzing tumor-immune interactions and TILs. Although the search results do not specifically mention the use of anti-BAFF antibodies in syngeneic models for tumor growth inhibition, such models are theoretically suitable for this purpose. They could be used to study how anti-BAFF antibodies modulate the immune response and affect TIL composition and function in the context of tumor growth. Humanized ModelsHumanized Models are used to mimic human immune responses and are particularly valuable for studying aspects of human immunology that are not easily replicable in animal models. These models typically involve the transplantation of human immune cells into immunocompromised mice, allowing researchers to study human immune responses in a controlled environment. While not specifically mentioned for anti-BAFF antibody studies, humanized models could potentially be used to explore the effects of BAFF inhibition on human TILs and tumor growth, providing insights into how these mechanisms might translate to human immunotherapy. In summary, while the search results do not provide specific examples of using research-grade anti-BAFF antibodies in these models, both syngeneic and humanized models could be utilized to study the effects of BAFF inhibition on tumor growth and TILs. Syngeneic models are particularly useful for studying immune responses within a fully functional mouse immune system, while humanized models offer insights into human immune responses. For a direct study on tumor growth inhibition and characterization of TILs using anti-BAFF antibodies, specific research would need to be conducted using these models. While the search results do not provide specific information on the use of Tabalumab in conjunction with checkpoint inhibitors like anti-CTLA-4 or anti-LAG-3 biosimilars in immune-oncology models, it is possible to infer a general approach based on the mechanisms of these drugs and how researchers might combine them. Understanding the Components
Potential Synergistic EffectsCombining Tabalumab with checkpoint inhibitors could theoretically modulate immune responses in several ways:
However, as of the latest research, there is no specific evidence of using Tabalumab directly in conjunction with these checkpoint inhibitors for synergistic effects in immune-oncology models. Future studies would be needed to explore these potential synergies. Example Experimental Design
This approach would allow researchers to evaluate whether combining Tabalumab with checkpoint inhibitors enhances antitumor immunity beyond what is achieved with either treatment alone. In the context of immunogenicity testing, a Tabalumab biosimilar can be used in a bridging ELISA to monitor a patient's immune response by serving as either a capture or detection reagent. However, Tabalumab itself is not explicitly mentioned in the search results as being used in such a manner. Nonetheless, the general principles of using biosimilars in bridging ELISA assays can be applied: Overview of Bridging ELISABridging ELISA is a technique used to detect and quantify antibodies against therapeutic drugs, such as biologics and monoclonal antibodies. It involves using the drug itself or a biosimilar as both capture and detection reagents to identify anti-drug antibodies (ADAs) in patient samples. Using Biosimilars in Bridging ELISA:
Benefits and Considerations:
Applicability to Tabalumab:While Tabalumab is not specifically mentioned in the context of bridging ELISA in the search results, the principles outlined above can be applied if a Tabalumab biosimilar were used in such assays. The key steps involve biotinylation for capture and enzyme conjugation for detection, with the biosimilar serving as both to identify ADAs against Tabalumab. To apply this method to Tabalumab, one would:
ConclusionIn summary, while specific details about using a Tabalumab biosimilar in a bridging ELISA are not provided in the search results, the general approach involves using biosimilars as capture and detection reagents to monitor patient immune responses against therapeutic drugs. This method is widely applicable to various biologics and can be adapted to any biosimilar, including those for Tabalumab, by following the standard bridging ELISA protocol. References & Citations1. Manetta, J. et al. (2014) J Inflamm Res. 7: 121–131 2. Clatworthy, MR. et al. (2013) Transplantation. 96(4): 413–420. 3. Lied, GA. and Berstad, A. (2011) Scand J Immunol. 73(1):1-7. 4. Büchler, JR. and Cano, MN. (1986) Jpn Heart J. 27(1):117-22. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1400 | |
LT1404 | |
LT1401 | |
LT1411 | |
LT1406 | |
LT1405 | |
LT1407 |
